Brief: Zenas Biopharma Announces Late-Breaking Platform Presentation Of Results From Phase 2 Moonstone Trial Of Obexelimab In Relapsing Multiple Sclerosis At Actrims Forum 2026
09/02/2026 12:09
Feb 9 (Reuters) - Zenas Biopharma Inc ZBIO.O: ZENAS BIOPHARMA ANNOUNCES LATE-BREAKING PLATFORM PRESENTATION OF RESULTS FROM PHASE 2 MOONSTONE TRIAL OF OBEXELIMAB IN RELAPSING MULTIPLE SCLEROSIS AT ACTRIMS FORUM 2026 Source text: ID:nGNX9WdBD2 Further company coverage: ZBIO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zenas BioPharma
See all newsBrief: Zenas Biopharma Announces Upcoming Presentations Of Obexelimab Data In Igg4-Related Disease At The Igg4ward! 6Th International Symposium On Igg4-Related Disease And Acr Convergence 2026
Brief: Zenas BioPharma Files For Offering Of Up To 7.0 Million Shares Of Common Stock By The Selling Stockholder - SEC Filing
Zenas BioPharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Zenas Biopharma Says Phase 3 Indigo Trial Of Obexelimab Meets Primary And All Key Secondary Endpoints